Hypersomnia Clinical Trial
Official title:
A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
NCT number | NCT05983731 |
Other study ID # | 321547 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 2023 |
Est. completion date | August 2025 |
The goal of this pilot observational study is to assess the ability of continuous 'home' EEG to accurately diagnose Narcolepsy in children and young people with hypersomnia. The main question[s]it aims to answer are: - can ambulatory home monitoring using a Dreem headband with a 'life as usual' unrestricted protocol allow accurate diagnosis of Narcolepsy, compared to gold standard in-patient PSG and MSLT - which EEG derived sleep parameters and study duration yield most diagnostic accuracy Participants undergoing investigation for hypersomnia will additionally be asked to wear a Dream Headband at night for weeknights, then continuously for 48 hours over the weekend. The data from the headband will then be analysed to see if it can predict the results of the polysomnography and MSLT that form routine clinical care.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | August 2025 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 25 Years |
Eligibility | Inclusion Criteria: - Participants already under investigation within GSTT children and adult sleep service for hypersomnolence - Age 12 to 25 years of age at recruitment - Participants able to understand patient information (information including DH instructions written only in English for this initial observational study) and who can provide written informed consent or assent. Exclusion Criteria: - Any physician diagnosed sleep disorder (e.g. sleep apnea) - Any physician diagnosed medical or psychiatric disorder that could explain their excessive daytime sleepiness - Regular use of either prescribed or recreational medication that affects sleep - Participation in another concurrent research study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust | University of Surrey |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of diagnosis of Narcolepsy Type 1 derived by Dreem Headband compared to standard ICSD-3 protocol | Sensitivity (%) of Dreem headband derived EEG in predicting a final diagnosis of Narcolepsy derived from gold standard in-patient clinical testing with polysomnography and multiple sleep latency test ICSD-3 protocol. | 2 years | |
Primary | Specificity of diagnosis of Narcolepsy Type 1 derived by Dreem Headband compared to standard ICSD-3 protocol | Specificity (%) of Dreem headband derived EEG in predicting a final diagnosis of Narcolepsy derived from gold standard in-patient clinical testing with polysomnography and multiple sleep latency test ICSD-3 protocol. | 2 years | |
Primary | Positive predictive value of diagnosis of Narcolepsy Type 1 derived by Dreem Headband compared to standard ICSD-3 protocol | Positive predictive value (%) of Dreem headband derived EEG in predicting a final diagnosis of Narcolepsy derived from gold standard in-patient clinical testing with polysomnography and multiple sleep latency test ICSD-3 protocol. | 2 years | |
Primary | Negative predictive value of diagnosis of Narcolepsy Type 1 derived by Dreem Headband compared to standard ICSD-3 protocol | Negative predictive value (%) of Dreem headband derived EEG in predicting a final diagnosis of Narcolepsy derived from gold standard in-patient clinical testing with polysomnography and multiple sleep latency test ICSD-3 protocol. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 | |
Completed |
NCT01183312 -
Flumazenil for the Treatment of Primary Hypersomnia
|
Phase 1/Phase 2 | |
Terminated |
NCT03198156 -
Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy
|
N/A | |
Completed |
NCT03682185 -
The Healthy Patterns Sleep Study
|
Phase 3 | |
Completed |
NCT00916253 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies
|
N/A | |
Completed |
NCT04157244 -
The Music, Sleep and Dementia Study
|
N/A | |
Recruiting |
NCT05443373 -
A Multi-Signal Based Monitoring System for CNS Hypersomnias
|
||
Completed |
NCT01877616 -
Sleep Disorders and Their Cardiovascular Correlates in Atahualpa.
|
N/A | |
Suspended |
NCT00427323 -
Light Exposure to Treat Sleep Disruption in Older People
|
N/A | |
Not yet recruiting |
NCT04300166 -
Telemedicine and Humidification for Cpap IN Osas Key Treatment (THINK Study)
|
N/A | |
Not yet recruiting |
NCT06404099 -
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
|
Phase 2 | |
Not yet recruiting |
NCT06404086 -
RECOVER-SLEEP: Platform Protocol
|
Phase 2 | |
Completed |
NCT01146600 -
Clarithromycin for the Treatment of Hypersomnia
|
Phase 2 | |
Withdrawn |
NCT05627388 -
Feasibility Study of At-Home EEG Monitoring for Hypersomnia
|
N/A | |
Completed |
NCT01764035 -
Mindfulness Therapy on Disrupted Sleep in Bipolar Disorder
|
N/A | |
Completed |
NCT03459300 -
Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia (Actisom dépistage)
|
||
Completed |
NCT00001664 -
Sleep Disorders of Patients With Diseases of the Nervous System
|
N/A | |
Recruiting |
NCT04201392 -
Sleep in Psychiatric Inpatients
|
||
Suspended |
NCT05230394 -
Patient Outcomes in Unattended and In- Lab Polysomnography
|
N/A | |
Terminated |
NCT01544465 -
Structured Physical Activity for Sleep Quality and Daytime Sleepiness in Patients With Parkinson's Disease
|
N/A |